Werewolf Therapeutics (NASDAQ:HOWL) Director Luke Evnin Sells 40,761 Shares of Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Director Luke Evnin sold 40,761 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $0.65, for a total transaction of $26,494.65. Following the completion of the sale, the director owned 2,413,158 shares of the company’s stock, valued at $1,568,552.70. This trade represents a 1.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Luke Evnin also recently made the following trade(s):

• On Wednesday, January 7th, Luke Evnin sold 11,915 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total value of $7,625.60.
• On Monday, January 5th, Luke Evnin sold 18,378 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.64, for a total value of $11,761.92.
• On Friday, January 2nd, Luke Evnin sold 18,568 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total value of $11,697.84.
• On Wednesday, December 31st, Luke Evnin sold 24,962 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.62, for a total value of $15,476.44.
• On Tuesday, December 30th, Luke Evnin sold 34,847 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $21,256.67.
• On Monday, December 29th, Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.61, for a total value of $66,249.66.
• On Friday, December 26th, Luke Evnin sold 35,632 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.63, for a total transaction of $22,448.16.
• On Wednesday, December 24th, Luke Evnin sold 16,310 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.65, for a total transaction of $10,601.50.
• On Tuesday, December 23rd, Luke Evnin sold 71,428 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.63, for a total transaction of $44,999.64.
• On Monday, December 22nd, Luke Evnin sold 59,307 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.69, for a total transaction of $40,921.83.

Werewolf Therapeutics Stock Down 0.1%

Werewolf Therapeutics stock opened at $0.64 on Thursday. The company’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.26. The company has a quick ratio of 3.87, a current ratio of 3.87 and a debt-to-equity ratio of 0.73. The stock has a market cap of $31.13 million, a P/E ratio of -0.40 and a beta of 0.77. Werewolf Therapeutics, Inc. has a twelve month low of $0.56 and a twelve month high of $2.38.

Werewolf Therapeutics (NASDAQ:HOWL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.03. As a group, analysts expect that Werewolf Therapeutics, Inc. will post -1.56 EPS for the current year.

Hedge Funds Weigh In On Werewolf Therapeutics

Hedge funds have recently bought and sold shares of the company. Quadrature Capital Ltd bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter worth approximately $28,000. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics during the second quarter valued at approximately $48,000. AQR Capital Management LLC bought a new stake in Werewolf Therapeutics during the first quarter worth $79,000. Y Intercept Hong Kong Ltd bought a new stake in Werewolf Therapeutics during the second quarter worth $92,000. Finally, Susquehanna International Group LLP boosted its holdings in shares of Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company’s stock valued at $183,000 after purchasing an additional 13,439 shares in the last quarter. 64.84% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on HOWL shares. Citizens Jmp cut Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, December 19th. Citigroup lowered shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Wedbush downgraded shares of Werewolf Therapeutics from an “outperform” rating to a “neutral” rating and set a $1.00 price objective for the company. in a report on Friday, December 19th. Zacks Research cut shares of Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, HC Wainwright cut their price target on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, December 19th. Three analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.